Clear market notes built around the JSE, the rand, and what matters locally.

2026-10-09 01:13 • The Motley Fool Positive Axe Cap view: Selective

Nebius Group and SoundHound AI represent different plays in the AI infrastructure boom. Nebius operates a specialized cloud platform for AI workloads with 350% revenue growth and demand exceeding supply, while SoundHound AI provides voice-enabled software with 99% revenue growth but faces profitability challenges and integration risks. The author recommends Nebius due to its stronger market position and less competitive landscape.

Axe note: Nebius Group’s AI cloud infrastructure growth looks stronger and more durable than SoundHound AI’s voice software struggles.

2026-10-09 01:09 • The Motley Fool Mixed Axe Cap view: Selective

The article compares two AI-focused tech stocks with opposite market approaches. BigBear.ai provides defense and government intelligence software but faces declining revenue (down 19% in 2025) and mounting losses ($294M net loss). Nebius Group operates AI cloud infrastructure with explosive 479% revenue growth in 2025 and positive net income of $82M, though it carries massive negative free cash flow due to capital-intensive GPU infrastructure spending. The author recommends Nebius as the better buy, citing its larger addressable market ($1 trillion GPU cloud opportunity), consistent profitability, and superior growth trajectory compared to BigBear.ai's struggling government contract model.

Axe note: Nebius’s explosive growth and profitability beat BigBear.ai’s struggling defense software model.

2026-10-09 00:43 • The Motley Fool Positive Axe Cap view: Selective

The article compares Bristol Myers Squibb and Pfizer as healthcare investment options for 2026. Both face patent cliffs and regulatory pressures, but Pfizer is recommended as the better choice due to its clearer post-patent roadmap, growing non-COVID products, obesity drug positioning, and committed dividend protection. Bristol Myers Squibb shows near-term momentum improvements but faces longer-term revenue uncertainty from patent losses and drug pricing reforms.

Axe note: Pfizer offers a clearer path past patent losses and drug pricing challenges than Bristol Myers Squibb.